Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of a Fractional Booster Dose of IPV Intradermally Versus Full Dose Intramuscularly

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 15 to 18 months on the day of inclusion~* Informed consent form signed by the parent(s) or other legally acceptable representative~* Subjects and parent/guardian able to attend all scheduled visits and comply with all trial procedures~* Child having completed all visits of the IPV25 study (NCT00604058), including the three-dose primary vaccination series with the study vaccine (IMOVAX Polio), using the route of administration as designated by randomization.~Exclusion Criteria:~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination~* Planned participation in another clinical trial during the present trial period~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator~* Receipt of blood or blood-derived products since birth that might interfere with the assessment of immune response~* Receipt of any vaccine in the 4 weeks preceding the trial vaccination~* Planned receipt of any vaccine during the present trial period~* Known personal or maternal Human Immunodeficiency Virus (HIV), Hepatitis B antigen or Hepatitis C seropositivity~* History of seizures~* History of poliomyelitis infection (confirmed either clinically, serologically or microbiologically)~* Previous fourth dose vaccination against the poliomyelitis disease with either the trial vaccine or another vaccine~* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating IM injection~* Febrile illness (temperature ≥38.0 °C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.

- Gender: ALL
- Minimum Age: 15 Months
- Maximum Age: 18 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Will receive fractional doses of IPV Intradermally
- Group B (Type: ACTIVE_COMPARATOR): Will receive full doses of IPV Intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).